ArticleThe Journal of infection2022
SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: Genomic surveillance in Japan from September 2021 to March 2022.
Abstract readLetterComment
In one paragraph
Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Forensic application of three interstitial pneumonia markers: search for new pneumonia markers in dead bodies.International journal of legal medicine · 2024Article
- Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein.Nature structural & molecular biology · 2023Article
- Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Genomic evidence for reinfection with different Omicron subvariants.The Journal of infection · 2023Article
- Lung tropism in hospitalized patients following infection with SARS-CoV-2 variants from D614G to Omicron BA.2.Communications medicine · 2023Article
- Attenuated humoral response against SARS-CoV-2 mRNA vaccination in allogeneic stem cell transplantation recipients.Cancer science · 2023Article
- Prolonged replication of BA.1 and BA.2 Omicron lineages compared to Delta variant in nasopharyngeal samples from COVID-19 patients.Infectious diseases now · 2023Article
- An age-dependent immuno-epidemiological model with distributed recovery and death rates.Journal of mathematical biology · 2023Article
- Detection of the Omicron BA.2.75 subvariant in Japan.The Journal of infection · 2023Article
- Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study.Open forum infectious diseases · 2022Article
- Prospective Clinical Evaluation of the Diagnostic Accuracy of a Highly Sensitive Rapid Antigen Test Using Silver Amplification Technology for Emerging SARS-CoV-2 Variants.Biomedicines · 2022Article
- Clinical Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Rapid Antigen Tests During the Omicron Wave in South Africa.The Journal of infectious diseases · 2022Article
- Adjusted control rate closely associated with the epidemiologic evolution of the recent COVID-19 wave in Shanghai, with 94.3% of all new cases being asymptomatic on first diagnosis.The Journal of infection · 2022Article
- Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization.medRxiv : the preprint server for health sciences · 2022Article
- Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths.Journal of personalized medicine · 2022Review
- Convolutional Neural Networks Based on Sequential Spike Predict the High Human Adaptation of SARS-CoV-2 Omicron Variants.Viruses · 2022Article
Corrections and comments
- Comment on
Authors and funding
12 authors.
Yosuke HirotsuGenome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: hirotsu-bdyu@ych.pref.yamanashi.jp.
Makoto MaejimaDivision of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: maejima-bdzs@ych.pref.yamanashi.jp.
Masahiro ShibusawaDivision of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: shibusawa-bdfb@ych.pref.yamanashi.jp.
Yume NatoriDivision of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: natori-bfxu@ych.pref.yamanashi.jp.
Yuki NagakuboDivision of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan; Division of Genetics and Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: nagakubo-bfjc@ych.pref.yamanashi.jp.
Kazuhiro HosakaDivision of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: hosaka-ampg@ych.pref.yamanashi.jp.
Hitomi SuekiDivision of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: h-sueki@ych.pref.yamanashi.jp.
Hitoshi MochizukiGenome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan; Central Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan; Department of Gastroenterology, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: h-mochiduki2a@ych.pref.yamanashi.jp.
Toshiharu TsutsuiLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: tsutsui-bfnh@ych.pref.yamanashi.jp.
Yumiko KakizakiLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: kakizaki-bfng@ych.pref.yamanashi.jp.
Yoshihiro MiyashitaLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. Electronic address: y-miyashita@ych.pref.yamanashi.jp.
Masao OmataDepartment of Gastroenterology, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan; The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. Electronic address: m-omata0901@ych.pref.yamanashi.jp.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19SARS-CoV-2Genome, ViralGenomicsHumansJapanBA.2Omicron, BA.1SARS-CoV-2Variant of concern
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.